{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T21:01:12Z","timestamp":1795122072300,"version":"4.10.3"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,12,1]]},"DOI":"10.2169\/internalmedicine.7490-21","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T22:11:28Z","timestamp":1622844688000},"page":"3759-3764","source":"Crossref","is-referenced-by-count":2,"title":["Renal Involvement as Rare Acute Tubulointerstitial Nephritis in a Patient with Eosinophilic Disorder Treated with Early Add-on Administration of Mepolizumab"],"prefix":"10.2169","volume":"60","author":[{"given":"Yuto","family":"Hayama","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminori","family":"Tomyo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Asakawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifuru","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Science, Faculty of Medical Technology, Teikyo University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of Integrated Diagnostic Pathology, Nippon Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Fujigaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis 2: 37, 2007.","DOI":"10.1186\/1750-1172-2-37"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52: 2926-2935, 2005.","DOI":"10.1002\/art.21250"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33: 1094-1100, 1990.","DOI":"10.1002\/art.1780330806"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Khoury P, Zagallo P, Talar-Williams C, et al. Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy 67: 1149-1156, 2012.","DOI":"10.1111\/j.1398-9995.2012.02873.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Saint-Pierre MD, Moran-Mendoza O. Acetaminophen use: an unusual cause of drug-induced pulmonary eosinophilia. Can Respir J 2016: 4287270, 2016.","DOI":"10.1155\/2016\/4287270"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Inoue D, Usui R, Nitta K, Koike M. A case of acetaminophen-induced acute tubulointerstitial nephritis in adult. CEN Case Rep 6: 185-188, 2017.","DOI":"10.1007\/s13730-017-0272-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65: 1-11, 2013.","DOI":"10.1007\/s10157-013-0869-6"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 63: 65-68, 1984.","DOI":"10.1097\/00005792-198403000-00001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 115: 284-290, 2003.","DOI":"10.1016\/S0002-9343(03)00359-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cogan E, Roufosse F. Clinical management of the hypereosinophilic syndromes. Expert Rev Hematol 5: 275-289, 2012.","DOI":"10.1586\/ehm.12.14"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lyons PA, Peters JE, Alberici F, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun 10: 5120, 2019.","DOI":"10.1038\/s41467-019-12515-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lef\u00e8vre G, Ackermann F, Kahn JE. Hypereosinophilia with asthma and systemic (non-vasculitic) manifestations: eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome? Autoimmun Rev 16: 208-209, 2017.","DOI":"10.1016\/j.autrev.2016.11.001"},{"key":"13","unstructured":"13. Cottin V, Bel E, Bottero P, et al.; Groupe d&apos;Etudes et de Recherche sur les Maladies Orphelines Pulmonaires (GERM &quot;O&quot; P). Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d&apos;Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev 16: 1-9, 2017."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Durel CA, Sinico RA, Teixeira V, et al.; French Vasculitis Study Group (FVSG). Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. Rheumatology (Oxford) 60: 359-365, 2021.","DOI":"10.1093\/rheumatology\/keaa416"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Davenport A, McDicken I, Goldsmith HJ. Reversible acute renal failure due to Churg-Strauss syndrome. Postgrad Med J 64: 713-715, 1988.","DOI":"10.1136\/pgmj.64.755.713"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 47: 770-779, 2006.","DOI":"10.1053\/j.ajkd.2006.01.026"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Chen Y, Ding Y, Liu Z, Zhang H, Liu Z, Hu W. Long-term outcomes in antineutrophil cytoplasmic autoantibody-positive eosinophilic granulomatosis with polyangiitis patients with renal involvement: a retrospective study of 14 Chinese patients. BMC Nephrol 17: 101, 2016.","DOI":"10.1186\/s12882-016-0319-2"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Spry CJ. The hypereosinophilic syndrome: clinical features, laboratory findings and treatment. Allergy 37: 539-551, 1982.","DOI":"10.1111\/j.1398-9995.1982.tb02339.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Shehwaro N, Langlois AL, Gueutin V, Izzedine H. Renal involvement in idiopathic hypereosinophic syndrome. Clin Kidney J 6: 272-276, 2013.","DOI":"10.1093\/ckj\/sft046"},{"key":"20","unstructured":"20. Motell\u00f3n JL, Bernis C, Garc\u00eda-S\u00e1nchez A, Gruss E, Traver JA. Renal involvement in the hypereosinophilic syndrome. Nephrol Dial Transplant 10: 401-403, 1995."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Bulucu F, Can C, Inal V, Baykal Y, Erik\u00e7i S. Renal involvement in a patient with idiopathic hypereosinophilic syndrome. Clin Nephrol 57: 171-173, 2002.","DOI":"10.5414\/CNP57171"},{"key":"22","first-page":"379","volume":"2","author":"I Navarro","year":"2009","unstructured":"22. Navarro I, Torras J, Gom\u00e0 M, Cruzado JM, Griny\u00f3 JM. Renal involvement as the first manifestation of hypereosinophilic syndrome: a case report. NDT Plus 2: 379-381, 2009.","journal-title":"NDT Plus","ISSN":"https:\/\/id.crossref.org\/issn\/1753-0784","issn-type":"print"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Raffray L, Guillevin L. Updates for the treatment of EGPA. Presse Med 49: 104036, 2020.","DOI":"10.1016\/j.lpm.2020.104036"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol 94: 1149-1167, 2019.","DOI":"10.1002\/ajh.25617"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Caminati M, Menzella F, Guidolin L, Senna G. Targeting eosinophils: severe asthma and beyond. Drugs Context 8: 212587, 2019.","DOI":"10.7573\/dic.212587"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wechsler ME, Akuthota P, Jayne D, et al.; EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med 376: 1921-1932, 2017.","DOI":"10.1056\/NEJMoa1702079"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Roufosse F, Kahn JE, Rothenberg ME, et al.; HES Mepolizumab study group. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol 146: 1397-1405, 2020.","DOI":"10.1016\/j.jaci.2020.08.037"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Koike H, Akiyama K, Saito T, Sobue G; Research Group for IVIg for EGPA\/CSS in Japan. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial. J Neurol 262: 752-759, 2015.","DOI":"10.1007\/s00415-014-7618-y"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/23\/60_7490-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T03:14:32Z","timestamp":1638587672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/23\/60_7490-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":28,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7490-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]},"article-number":"7490-21"}}